Table 1.
Clinicopathologic characteristics of patients with acinic cell carcinoma of the breast in this cohort.
| Case Designation | Age at Diagnosis | Tumor size (cm) | Axillary lymph node status | Specimen Type | Histomorphology | IHC Results (for the AciCC component in cases with mixed histology) (+), positive; (−), negative |
FISH Results |
|---|---|---|---|---|---|---|---|
| 1 | 48 | 9.5 | Negative (0 of 1) | Mastectomy | Pure AciCC | (+) S100, lysozyme, A1ACT (−) CK5/6, p63, ER, NR4A3, DOG-1 |
Testing attempted; no results obtained |
| 2 | 45 | 10.5 | Negative (0 of 2) | Excision; completion mastectomy | Pure AciCC | (+) S100, ER (20–30%, weak-to-moderate), lysozyme, A1ACT, A1AT (−) PR, HER2, NR4A3, DOG-1 |
Negative for NR4A3 rearrangement; polysomy detected in 58% of nuclei |
| 3 | 32 | 2.5 | Negative (0 of 2) | Mastectomy | AciCC admixed with chondroid metaplastic carcinoma | (+) S100, lysozyme, A1ACT (−) ER, PR, HER2, NR4A3, DOG-1 |
Testing attempted; no results obtained |
| 4 | 46 | Unknown | Unknown | CNB | AciCC admixed with microinvasive carcinoma NST | (+) S100, EMA, PR (80%, moderate) (−) ER, HER2, p63, NR4A3, DOG-1 |
Negative for NR4A3 rearrangement; polysomy detected in 56% of nuclei |
| 5 | 58 | 0.6 | Negative (0 of 2) | Mastectomy | Pure AciCC | (+) GATA3, CK7, S100, lysozyme, A1AT (−) ER, PR, HER2, synaptophysin, chromogranin, CK20, NR4A3, DOG-1 |
Negative for NR4A3 rearrangement |
| 6* | 36 | 5.0 | Positive (10 of 17) | Unknown | AciCC admixed with invasive carcinoma NST | (+) lysozyme (−) ER, PR, HER2, NR4A3, DOG-1 |
Not tested |
| 7* | 55 | 1.9 | Negative (0 of 8) | Unknown | AciCC admixed with invasive carcinoma NST | (+) lysozyme (−) ER, PR, HER2, NR4A3, DOG-1 |
Not tested |
| 8* | 34 | 3.6 | Negative (0 of 3) | Unknown | AciCC admixed with invasive carcinoma NST | (+) lysozyme (−) ER, PR, HER2, NR4A3, DOG-1 |
Not tested |
| 9* | 70 | Unknown | Unknown | Unknown | AciCC admixed with chondroid metaplastic carcinoma | (+) lysozyme (−) ER, PR, HER2, NR4A3, DOG-1 |
Not tested |
| 10 | 70 | 1.8 | Negative (ITC in 1 of 4) | Excision | Pure AciCC | (+) S100, lysozyme, SOX10 (−) ER, PR, HER2, NR4A3, DOG-1 |
Not tested |
| 11† | 74 | 1.2 | Unknown | CNB | Pure AciCC | (+) PR (1%, weak), S100, lysozyme, SOX10 (−) ER, NR4A3, DOG-1 | Testing attempted; no results obtained |
| 12 | 29 | 1.5 | Negative (0 of 3) | CNB; excision | AciCC admixed with invasive carcinoma NST; multiple residual foci of pure AciCC invasion after neoadjuvant chemotherapy | (+) GATA3, GCDFP-15, S100, lysozyme, A1AT, PR (30%, moderate) (−) ER, HER2, NR4A3, DOG-1 |
Testing attempted; no results obtained |
| 13† | 43 | Unknown | Unknown | CNB | Pure AciCC | (+) S100, EMA, lysozyme, A1AT (−) ER, PR, HER2, NR4A3, DOG-1 |
Testing attempted; no results obtained |
| 14 | 46 | 1.1 | Negative (0 of 1) | Mastectomy | Dominant mass pure AciCC; separate focus of invasive carcinoma NST (0.55 cm) | (+) PR (30%, weak), GATA3, SOX10, S100, lysozyme, A1AT, DOG-1 (focal) (−) ER, HER2, BCL10, NR4A3 |
Negative for NR4A3 rearrangement; polysomy detected in 48% of nuclei |
| 15 | 38 | 2.9 | Negative (0 of 1) | Mastectomy | Pure AciCC | (+) S100, EMA, GCDFP-15, SOX10, AR, lysozyme, A1AT, MUC4, DOG-1 (focal) (−) ER, PR, HER2, synaptophysin, mammaglobin, pan-TRK, NR4A3 |
Not tested |
| 16 | 52 | 6.3 | Unknown | Mastectomy | AciCC admixed with spindle cell metaplastic carcinoma | (+) pan-keratin MNF-116, AE1/AE3, Cam5.2, S100, lysozyme, A1AT, GCDFP-15 (−) ER, PR, HER2, CK5, 34βE12, p63, NR4A3, DOG-1 |
Not tested |
Notes:
*
Cases 6, 7, 8, and 9 in this current study have been published in a previous study5 (corresponding to case designations 7, 9, 14, and 16 in that study), and are further characterized herein.
†
For cases 11 and 13, only a core needle biopsy (CNB) specimen was available for analysis, each of which showed pure AciCC morphology.
Abbreviations: AciCC, acinic cell carcinoma; A1ACT, alpha-1-antichymotrypsin; A1AT, alpha-1-antitrypsin; AR, androgen receptor; CK, cytokeratin; ER, estrogen receptor; EMA, epithelial membrane antigen; GCDFP-15, gross cystic disease fluid protein 15; PR, progesterone receptor.